Yesterday afternoon, Celgene Corporation (NASDAQ:CELG) hosted an analyst event with special attention to protein homeostasis. On the heels of the event, Piper Jaffray analyst …
Today, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) announced the completion of a rolling submission of New Drug Application (NDA) to the …
Biogen Inc (NASDAQ:BIIB) is riding the tide of good news after a recent publication has indicated the mechanism in the biotech giant’s pipeline …
Yesterday, Gilead Sciences, Inc. (NASDAQ:GILD) announced it was halting its Phase 2/3 clinical study of GS-5745, an anti-MMP9 antibody designed to treat patients …
Piper Jaffray analyst Joshua Schimmer is out with a research report on shares of Gilead Sciences, Inc. (NASDAQ:GILD), reiterating an Overweight rating with …
Company positioned for better long-term growth by keeping HIV and HCV franchises together, says Piper Jaffray
Piper Jaffray remains skeptical about relaunch strategies and their impact on Afrezza’s prescription numbers.
Piper Jaffray reduced the price target to $95, while reiterating Overweight
Piper Jaffray analyst Joshua Schimmer provides a 2H16 outlook on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). Exiting second-quarter earnings season, GWPH remains one of …
Piper Jaffray analyst Joshua Schimmer provides an outlook for Gilead Sciences, Inc. (NASDAQ:GILD) as well as expectations for its clinical development moving forward.
